Portfolio Companies

NeXeption is actively seeking additional development-ready assets across a broad range of therapeutic areas.

For more information, contact us.

 

Active

Aclaris Therapeutics

 

A specialty pharmaceutical company focused on identifying, developing and commercializing innovative and differentiated drugs to address significant unmet needs in dermatology. The company was founded in 2012 and is based in Malvern, PA.

Ralexar Therapeutics

 

A privately held specialty pharmaceutical company developing topical and systemic therapies based on Liver X Receptor (LXR) modulators. Ralexar is developing its lead compound for the treatment of various dermatological conditions. The company was founded in 2014 and is based in Malvern, PA. 

Velicept Therapeutics

 

A privately held, clinical development company focused on advancing best-in-class compounds with the potential to fill unmet medical needs. Its lead program, solabegron, is a highly differentiated novel compound being investigated for overactive bladder (OAB) and irritable bowel syndrome (IBS). The company was founded through an acquisition in 2015 and is based in Malvern, PA.

Onspira Therapeutics

 

Onspira Therapeutics is focused on the development of life-changing medicines to bring hope to patients suffering from rare pulmonary diseases. Its lead program is a novel, inhaled IL-1 (beta) antagonist protein being advanced for the treatment of bronchiolitis obliterans syndrome (BOS) in post-lung transplant patients. BOS is a significant, often fatal condition affecting thousands of patients around the world. Additional programs will address interstitial pulmonary fibrosis and cystic fibrosis. Onspira was founded in 2017 and is based in Malvern, PA.

Onspira Therapeutics

 

Onspira Therapeutics is focused on the development of life-changing medicines to bring hope to patients suffering from rare pulmonary diseases. Its lead program is a novel, inhaled IL-1 (beta) antagonist protein being advanced for the treatment of bronchiolitis obliterans syndrome (BOS) in post-lung transplant patients. BOS is a significant, often fatal condition affecting thousands of patients around the world. Additional programs will address interstitial pulmonary fibrosis and cystic fibrosis. Onspira was founded in 2017 and is based in Malvern, PA.

NexEos Diagnostics, Inc.

 

NexEos Diagnostics, Inc. is a privately held medical diagnostics company dedicated to improving the diagnosis, life-long management and treatment of patients living with chronic, eosinophil-related inflammatory diseases.   Through the licensing, development and commercialization of novel technologies, NexEos Diagnostics, Inc. is bringing new tools to market that address the unmet needs of patients suffering with eosinophil-related diseases.  Its lead program is a novel, rapid imaging agent for the diagnosis, treatment monitoring and management of eosinophilic esophagitis (EoE) to allow patients to maintain a quality life and halt their disease progression.

Acquired

Our experienced team of pharmaceutical and biotechnology executives has a proven track record of identifying, developing, registering and commercializing new products. The following companies formed by members of the management team have been successfully partnered, generating high returns for investors.

Ceptaris Therapeutics

 

A privately held specialty pharmaceutical company focused on the development of a product for the treatment of early stage cutaneous T-cell lymphoma (MF-CTCL). Its lead product, VALCHLOR® was approved by the FDA in August of 2013 and the company was acquired by Actelion at the time of approval.

Vicept Therapeutics 

 

A privately held specialty pharmaceutical company focused on the development of a topical product for the treatment of rosacea. The company was acquired by Allergan in 2011 and the development of its lead asset is ongoing.

Ception Therapeutics

 

A privately held biopharma company focused on the discovery and development of novel products to address areas of unmet medical need. The company's lead asset was reslizumab, an anti IL5 monoclonal antibody, for the treatment of severe asthma. The company was acquired by Cephalon in 2010 and the development of its lead asset, reslizumab, is ongoing. 

Trigenesis Therapeutics

 

Specialty dermatology company formed to advance multiple topical programs. The company was acquired by Dr. Reddy’s Laboratories.